Panuveitis Market Report 2026

The panuveitis market size has grown rapidly in recent years. It will grow from $4.46 billion in 2025 to $4.91 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to limited awareness of panuveitis, reliance on conventional corticosteroid therapies, low accessibility to ophthalmology specialists, fragmented treatment infrastructure, slow adoption of diagnostic imaging technologies.

The panuveitis market size is expected to see strong growth in the next few years. It will grow to $7.14 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in biologics and immunomodulatory drugs, increasing prevalence of autoimmune and infectious eye disorders, growth in teleophthalmology services, rising investments in ai-assisted diagnostics, expansion of hospital and retail pharmacy distribution channels. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising use of teleophthalmology and remote monitoring, integration of ai-based diagnostic tools for eye inflammation, growth in personalized treatment approaches, expansion of specialized ophthalmology centers.

The rising prevalence of autoimmune disorders is expected to drive growth in the panuveitis market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy cells and tissues. Factors contributing to the increase in autoimmune disorders include genetic predispositions, environmental influences such as pollution and dietary changes, and greater exposure to infections and stressors that may trigger immune system dysregulation. The link between autoimmune activity and panuveitis has spurred research into immune system modulation, advancing treatment options. For instance, in May 2023, the University of Oxford, a UK-based research institution, reported that autoimmune disorders affect 10% of the global population, with 13% of women and 7% of men impacted. Therefore, the rising prevalence of autoimmune disorders is boosting the growth of the panuveitis market.

Companies in the panuveitis market are also focusing on innovative therapies, such as oral TYK2/JAK-1 inhibitors, to gain a competitive edge. These small-molecule immunomodulators block inflammatory signaling pathways by inhibiting both TYK2 and JAK-1 kinases, thereby reducing cytokine-driven inflammation in the eye. For example, in April 2024, Roivant Sciences, a US-based biopharmaceutical company, reported positive mid-stage clinical results for brepocitinib from its NEPTUNE study in non-infectious uveitis, including panuveitis. The drug effectively reduced inflammation and macular edema and was well tolerated, showing no new safety concerns. Similarly, in June 2023, Alumis, a US biotherapeutics company, began Phase 2 proof-of-concept dosing of ESK-001 for non-infectious uveitis, including panuveitis. This molecule is highly selective, orally bioavailable, and designed to minimize off-target effects through allosteric TYK2 inhibition.

In July 2023, Harrow Health Inc., a US-based pharmaceutical company, acquired Santen Pharmaceutical Co., Ltd. for an undisclosed amount. This acquisition allows Harrow to expand its portfolio by leveraging Santen’s expertise in innovative treatments for uveitis and panuveitis. Santen Pharmaceutical Co., Ltd., based in Japan, specializes in therapies for panuveitis.

Major companies operating in the panuveitis market are Pfizer Inc., AbbVie, Amgen, Mallinckrodt plc, EyePoint Pharmaceuticals Inc., Clearside Biomedical Inc., pSivida Corp., Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Novartis AG, F Hoffmann‑La Roche AG, Regeneron Pharmaceuticals Inc, Sanofi S A, Bausch Health Companies Inc, Johnson & Johnson, UCB SA, Aldeyra Therapeutics Inc, Kiora Pharmaceuticals Inc, Lux Biosciences Inc, Aciont Inc, Sirion Therapeutics Inc, EyeGate Pharmaceuticals Inc, Oculis Pharma AG, Alcon Inc, Sun Pharmaceutical Industries Ltd, Aerie Pharmaceuticals Inc.

North America was the largest region in the panuveitis market in 2025. The regions covered in the panuveitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the panuveitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the panuveitis market by increasing the cost of imported biologics, pharmacological agents, and ophthalmic surgical instruments. Hospital pharmacies, retail pharmacies, and online pharmacy platforms in north america, europe, and asia-pacific are the most affected due to dependence on imported treatments and equipment. While tariffs raise cost pressures, they also encourage domestic production, support innovation in targeted therapies and ai diagnostics, and improve local supply chain resilience.

The panuveitis market research report is one of a series of new reports that provides panuveitis market statistics, including panuveitis industry global market size, regional shares, competitors with a panuveitis market share, detailed panuveitis market segments, market trends and opportunities, and any further data you may need to thrive in the panuveitis industry. This panuveitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Panuveitis is an eye condition involving inflammation of all three layers of the uvea - the iris, ciliary body, and choroid. If left untreated, it can cause eye pain, blurred vision, and may lead to permanent vision loss. Treatment aims to control inflammation, relieve symptoms, and prevent further damage, making timely intervention critical for maintaining eye health and preserving vision.

The main types of panuveitis are infectious and non-infectious panuveitis. Infectious panuveitis occurs when inflammation is triggered by infectious agents, requiring prompt diagnosis and treatment to prevent serious eye complications. Treatments include pharmacological therapy, surgical intervention, and phototherapy, administered via oral, intravitreal, and topical routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The panuveitis market consists of revenues earned by entities providing services such as pharmaceutical treatment, surgical interventions, diagnostic services, and supportive care. The market value includes the value of related goods sold by the service providers or included within the service offering. The panuveitis market also includes sales of diagnostic tools, pharmaceuticals, biologic agents, immunosuppressive drugs, and supportive care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.